Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 301 AL 315

Novel aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment

Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H.

Curr Pharm Des. 2011;17(25):2594-602. doi: 10.2174/138161211797416039.

Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments

Reiman EM; Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S44-7. doi: 10.1016/j.neurobiolaging.2011.09.007. Epub 2011 Oct 7.

Clinical trial methodologies for disease-modifying therapeutic approaches

Aisen PS.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S64-6. doi: 10.1016/j.neurobiolaging.2011.09.008. Epub 2011 Oct 8.

Aβ-degrading enzymes: potential for treatment of Alzheimer disease

Miners JS, Barua N, Kehoe PG, Gill S, Love S.

J Neuropathol Exp Neurol. 2011 Nov;70(11):944-59. doi: 10.1097/NEN.0b013e3182345e46.

Risk-takers wanted

Nat Med. 2011 Nov 7;17(11):1321. doi: 10.1038/nm.2573.

Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies

Seibyl J, Zubal IG, Jennings D, Marek K, Doraiswamy PM.

Expert Rev Neurother. 2011 Dec;11(12):1783-93. doi: 10.1586/ern.11.168.

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

Klunk WE.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S20-36. doi: 10.1016/j.neurobiolaging.2011.09.006.

Alliance for aging research AD biomarkers work group: structural MRI

Jack CR Jr.

Neurobiol Aging. 2011 Dec;32 Suppl 1(0 1):S48-57. doi: 10.1016/j.neurobiolaging.2011.09.011.

Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets

Lee VM, Brunden KR, Hutton M, Trojanowski JQ.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006437. doi: 10.1101/cshperspect.a006437.

C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome

Banu S, Jabir NR, Manjunath CN, Shakil S, Kamal MA.

CNS Neurol Disord Drug Targets. 2011 Dec;10(8):921-7. doi: 10.2174/187152711799219271.

The cerebrovascular role of the cholinergic neural system in Alzheimer's disease

Van Beek AH, Claassen JA.

Behav Brain Res. 2011 Aug 10;221(2):537-42. doi: 10.1016/j.bbr.2009.12.047. Epub 2010 Jan 7.

Novel insights for the treatment of Alzheimer's disease

Kurz A, Perneczky R.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):373-9. doi: 10.1016/j.pnpbp.2010.07.018. Epub 2010 Jul 23.

Drosophila as a model to study age-related neurodegenerative disorders: Alzheimer's disease

Bonner JM, Boulianne GL.

Exp Gerontol. 2011 May;46(5):335-9. doi: 10.1016/j.exger.2010.08.004. Epub 2010 Aug 16.

Alzheimer's disease: effects of β-amyloid on mitochondria

Tillement L, Lecanu L, Papadopoulos V.

Mitochondrion. 2011 Jan;11(1):13-21. doi: 10.1016/j.mito.2010.08.009. Epub 2010 Sep 15.

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative

Villard V, Espallergues J, Keller E, Vamvakides A, Maurice T.

J Psychopharmacol. 2011 Aug;25(8):1101-17. doi: 10.1177/0269881110379286. Epub 2010 Sep 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias